dc.contributor.author |
Palega, Daniela |
|
dc.contributor.author |
Palii, Ina |
|
dc.date.accessioned |
2022-11-10T13:26:01Z |
|
dc.date.available |
2022-11-10T13:26:01Z |
|
dc.date.issued |
2022 |
|
dc.identifier.citation |
PALEGA, Daniela, PALII, Ina. The efficiency of a specific treatment in a child with pulmonary arterial hypertension: [poster]. In: Conferinţa ştiinţifică anuală "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță", 19-21 octombrie 2022: culegere de postere electronice. 2022, p. 185. |
en_US |
dc.identifier.uri |
https://conferinta.usmf.md/wp-content/uploads/culegere_de_postere_2022.pdf |
|
dc.identifier.uri |
http://repository.usmf.md/handle/20.500.12710/22355 |
|
dc.description.abstract |
Introduction- Pulmonaryarterial hypertension (PAH) is a severe disease that requests modern methods of
diagnosis as cardiac catheterization and a timely initiated specific treatment with Bosentan and Sildenafil contributes to a significant improvement of the health condition.
Purpose- To present a case report of a child with PAH treated with Bosentan and Sildenafil with dynamic evaluation of the efficiency criteria.
Material and methods- A 5 years old child was diagnosed by ECHO and CT with CHD, PAD (7 mm length and 9*7 mm in diameter) and severe PAH (mPAP- 70 mm/Hg). According to cardiac catheterization data PVR/SVRratio - 1.03, the surgery is questionable. Initiated Sildenafil 10 mg 3 times/day and Bosentan 16 mg 2 times/day gives us better results at 6 and 12 months for following criteria:
FC WHO/NYHA,
Oxygen saturation
6MWT (6-min walk test)
mPAP (mean pulmonary artery pressure)
PVR (pulmonary vascular resistance)
Conclusions- The combined and specific treatment with Bosentan and Sildenafil initiated in children with PAH reveals a significant positive dynamic of
the efficiency criteria. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Universitatea de Stat de Medicină şi Farmacie "Nicolae Testemiţanu" din Republica Moldova |
en_US |
dc.relation.ispartof |
Conferinţa ştiinţifică anuală "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță", 2022 |
en_US |
dc.subject |
Pulmonary hypertension |
en_US |
dc.subject |
specific therapy |
en_US |
dc.subject |
children |
en_US |
dc.subject |
CHD |
en_US |
dc.title |
The efficiency of a specific treatment in a child with pulmonary arterial hypertension |
en_US |
dc.type |
Other |
en_US |